临床病原菌鲍曼不动杆菌的实验室数据分析及防治对策

Clinical pathogens acinetobacter baumannii laboratory data analysis and Countermeasures to prevent and control

目的分析临床病原菌鲍曼不动杆菌的实验室检测数据、监测其耐药性及探讨防治策略,为临床提供合理有效抗感染治疗参考依据。方法使用Microscan Walkaway40对鲍曼不动杆菌菌株进行鉴定和药物敏感试验。结果该院鲍曼不动杆菌临床感染以老年患者居多,50岁以上老人占82.8%(372/449);呼吸道标本分离率最高(占90.2%);病区分布以呼吸内科最多(占30%),ICU次之(占27%)。鲍曼不动杆菌对常见抗菌药物均产生了较高的耐药率,仅亚胺培南的耐药率略低外(49.4%),其余均大于60%。结论鲍曼不动杆菌成为引起老年患者下呼吸道感染和重症监护患者感染的非发酵糖的主要病原菌之一,耐药性愈加严重,多重耐药菌株不断增多,给临床抗感染治疗带来了巨大的挑战。

Objective To analyse laboratory testing data of the clinical pathogen A.baumannii,and monitor the drug-resistant rate and discusses control strategy,and provide reasonable and effective basis for clinical anti-infection treatment.Methods Use the Microscan Walkaway 40 to identify A.baumannii strains and do drug sensitive test.Results The elderly patients were in the majority for clinical A.baumannii infection in our hospital,the Patients older than 60 years were 65.7%（295/449）;Lower respiratory specimen constituent ratio reached as high as 90.2%;Pneumology Department separation rate was the highest（30%）,followed by ICU（27%）;A.baumannii has produced higher drug-resistant rate to commom antibacterial,except the drug-resistant rate to imipenem was lower（49.4%）,the rest drugs were more than 60%.Conclusion A.baumannii was one of the main non-fermentative pathogenic bacteria making elderly and intensive care patients suffer from lower respiratory tract infection,the drug-resistant was more and more serious,multiple drug-resistant strains of A.baumannii became increasing,this brought huge challenge for clinical anti-infection treatment.